These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7595377)

  • 1. Efficient replication of human immunodeficiency virus type 1 and measles virus in a human-to-mouse graft versus host disease model permits immunization research.
    Huppes W; Smit V
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2707-15. PubMed ID: 7595377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model.
    Schutten M; Tenner-Racz K; Racz P; van Bekkum DW; Osterhaus AD
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1667-75. PubMed ID: 8760413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.
    Iankov ID; Pandey M; Harvey M; Griesmann GE; Federspiel MJ; Russell SJ
    J Virol; 2006 Sep; 80(17):8530-40. PubMed ID: 16912303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical measles after measles virus challenge in simian immunodeficiency virus-infected measles virus-vaccinated rhesus monkeys.
    Permar SR; Rao SS; Sun Y; Bao S; Buzby AP; Kang HH; Letvin NL
    J Infect Dis; 2007 Dec; 196(12):1784-93. PubMed ID: 18190259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1.
    Gauduin MC; Weir R; Fung MS; Koup RA
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):205-11. PubMed ID: 9491910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
    Bukawa H; Sekigawa K; Hamajima K; Fukushima J; Yamada Y; Kiyono H; Okuda K
    Nat Med; 1995 Jul; 1(7):681-5. PubMed ID: 7585151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Hamajima K; Shigematsu T; Yamamato A; Kawamoto S
    J Clin Lab Immunol; 1993; 40(3):97-113. PubMed ID: 7877154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles.
    Harris SJ; Gearing AJ; Layton GT; Adams SE; Kingsman AJ
    Immunology; 1992 Nov; 77(3):315-21. PubMed ID: 1362183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
    Gauduin MC; Safrit JT; Weir R; Fung MS; Koup RA
    J Infect Dis; 1995 May; 171(5):1203-9. PubMed ID: 7751695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies.
    Ziegler D; Fournier P; Berbers GA; Steuer H; Wiesmüller KH; Fleckenstein B; Schneider F; Jung G; King CC; Muller CP
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2479-89. PubMed ID: 8887481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.